Navigation Links
RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments

IRVING, Texas--(BUSINESS WIRE)--Jun 29, 2007 - Reata Pharmaceuticals, Inc. today announced the presentation of new preclinical data showing their lead anti-cancer agent, the Synthetic Triterpenoid RTA 402, is effective at protecting against common toxicities caused by traditional cancer treatments. This data was presented at the annual meeting of the Multinational Association of Supportive Care in Cancer (MASSC) in St Gallen, Switzerland.

Reata scientists and collaborators presented data showing that when RTA 402 is given in combination with radiation therapy to rats bearing human lung cancer tumors, the drug protected non-cancerous tissue from radiation damage while simultaneously enhancing the anti-tumor effect of the radiation treatment. The senior author of this presentation was Dr. Stephen Sonis of the Harvard Medical School, a well-known expert on cancer supportive care. RTA 402 is a novel, orally administered targeted therapy that inhibits the transcriptional activity of NF-kB and STAT3. Correlative studies presented at MASSC confirmed that RTA 402 inhibited NF-kB in both tumor and normal tissue and decreased many circulating inflammatory cytokines in the animals including TNF(alpha), MMP-9, IL-6, IL-8, and VEGF. In related studies, administration of RTA 402 reduced the duration and severity of radiation and chemotherapy-induced oral mucositis in hamster models of the disease and improved survival in animals receiving toxic doses of two common chemotherapy treatments, doxorubicin and oxaliplatin.

Confirmation of these preclinical results in the ongoing clinical trials of RTA 402 would make the drug an important addition to current treatment regimens. Radiation and chemotherapy cause unpleasant and life-threatening side effects in cancer patients. These therapy-related side effects are often dose limiting and cause delays in treatment or a reduction in treatment intensity, hampering the anti-cancer effects of the treatment. Consequently, an agent that reduces these toxicities and also has a significant direct anti-cancer effect would likely gain rapid acceptance in a variety of first-line and second-line treatment settings.

RTA 402 has recently begun Phase 2 clinical studies in cancer patients. An ongoing Phase 1 study in cancer patients has indicated that RTA 402 has potent single-agent anti-cancer activity in patients with several different types of tumors, is well tolerated with only mild, transient side effects, and suppresses its target proteins NF-kB and STAT3 in human tumors. A Phase 1/2 study of RTA 402 in combination with gemcitabine is underway in patients with pancreatic cancer. Analogues of RTA 402 are in advanced preclinical development for cancer, anti-inflammatory, and neurodegenerative indications.

About Reata

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on selecting and discovering promising early drug development opportunities and translating them into successful marketed drugs that target major unmet clinical needs in cancer, inflammation and neurodegenerative disease. The company's two lead programs are entering advanced clinical trials for deadly, late-stage cancers. In parallel with its clinical development, Reata is advancing a breakthrough drug discovery platform using protein misfolding, identified as a key factor in cancer and neurodegenerative disease, to feed its pipeline of small molecule therapeutic candidates. Reata takes a new and different approach to biotechnology, managing its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval. Founded in 2002, Reata is based in the Dallas area. For more information, visit www.reatapharma.com

Contact

Media:
For Reata Pharmaceuticals, Inc.
Kathryn Morris, 845-635-9828
kathryn@kmorrispr.com


'"/>




Related medicine technology :

1. Gabapentin Shown Effective for Fibromyalgia Pain
2. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
3. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
4. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
5. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
6. RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer
7. Accelreon Pharmas ACE-031Shown to Increase Muscle Mass in Preclinical Studies
8. Cethromycin Shown Effective Against Anthrax in Study
9. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
10. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
11. Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):